Skip to main content

Anika Therapeutics - Fundamentalanalyse - Jahresbericht / Bilanz / Geschäftsbericht

Anika Therapeutics (ISIN: US0352551081, WKN: 889120) Kursdatum: 21.07.2017 Kurs: 47,910 USD
Beschreibung Daten
Symbol ANIK
Marktkapitalisierung 724.207.552,00 USD
Land Vereinigte Staaten von Amerika
Indizes NASDAQ Comp.
Sektor Pharma
Rohdaten nach US GAAP in Millionen USD
Aktiensplits
Internet
Letztes Bilanz Update 24.02.2017

Fundamentaldaten

Fundamental Verhältnisse errechnet am: 21.07.2017
KFCV KCV DIV Rendite GKR EKQ KGV KUV KBV
74,00 30,43 0,00% 13,53 92,73 22,28 7,01 3,25

Firmenbeschreibung

18. Quarterly Financial Data (Unaudited)   Year 2015   Quarter ended December 31,   Quarter ended September 30,   Quarter ended June 30,   Quarter ended March 31, Product revenue   $ 25,607     $ 23,676     $ 22,898     $ 15,515   Total revenue     30,894       23,681       22,904       15,520   Cost of product revenue     6,290       5,176       5,274       4,313   Gross profit on product revenue     19,317       18,500       17,624       11,202   Net income   $ 11,042     $ 8,380     $ 7,820     $ 3,516   Per common share information:                                 Basic net income per share   $ 0.74     $ 0.56     $ 0.52     $ 0.24   Basic common shares outstanding     14,965       14,967       14,961       14,905   Diluted net income per share   $ 0.72     $ 0.55     $ 0.51     $ 0.23   Diluted common shares outstanding     15,353       15,316       15,336       15,330     Year 2014   Quarter ended December 31,   Quarter ended September 30,   Quarter ended June 30,   Quarter ended March 31, Product revenue   $ 17,880     $ 21,975     $ 21,267     $ 14,352   Total revenue     23,255       22,055       26,275       34,010   Cost of product revenue     5,511       5,725       5,333       4,361   Gross profit on product revenue     12,369       16,250       15,934       9,991   Net income   $ 7,816     $ 6,171     $ 9,302     $ 15,030   Per common share information:                                 Basic net income per share   $ 0.53     $ 0.42     $ 0.63     $ 1.04   Basic common shares outstanding     14,801       14,759       14,688       14,461   Diluted net income per share   $ 0.51     $ 0.40     $ 0.60     $ 0.97   Diluted common shares outstanding     15,278       15,435       15,493       15,499  

Firmenstrategie

Principles of Consolidation The accompanying consolidated financial statements include the accounts of Anika Therapeutics, Inc. and its wholly owned subsidiaries, Anika Securities, Inc. (a Massachusetts Securities Corporation), and Anika Therapeutics S.r.l. All intercompany balances and transactions have been eliminated in consolidation. Certain prior period amounts have been reclassified to conform to the current period presentation. There was no impact on operating income.

RevenueRecognitionPolicyTextBlock

Revenue Recognition - General

 

The Company recognizes revenue when all of the following criteria are met: persuasive evidence of an arrangement exists, risk of loss has passed or services have been rendered, the seller's price to the buyer is fixed or determinable, and collection from the customer is reasonably assured.

SegmentReportingDisclosureTextBlock

16. Revenue by Product Group, by Significant Customer and by Geographic Region; Geographic Information

 

 

 

Product revenue by product group is as follows (in thousands, except percentages):

 

 

 

 

 

    Years Ended December 31,
    2015   2014   2013
    Revenue   Percentage of Product Revenue   Revenue   Percentage of Product Revenue   Revenue   Percentage of Product Revenue
Orthobiologics   $ 73,247       84 %   $ 61,957       82 %   $ 55,956       78 %
Dermal     2,266       2 %     1,334       2 %     1,817       3 %
Surgical     5,812       7 %     5,855       8 %     5,446       8 %
Other     6,371       7 %     6,328       8 %     8,555       11 %
    $ 87,696       100 %   $ 75,474       100 %   $ 71,774       100 %

 

 

 

 

Product revenue by significant customers as a percent of product revenues is as follows:

 

 

 

 

 

    Percentage of Product Revenue
Years Ended December 31,
    2015   2014   2013
Mitek     72 %     72 %     63 %
Boehringer     5 %     4 %     5 %
Medtronic     3 %     4 %     3 %
Nordic Pharma     2 %     2 %     2 %
Pharmascience     2 %     2 %     3 %
      84 %     84 %     76 %

 

 

 

 

Total revenue by geographic location based on the location of the customer in total and as a percentage of total revenue are as follows (in thousands, except percentages):

 

 

 

 

 

 

    Years Ended December 31,
    2015   2014   2013
    Total
Revenue
  Percentage of
Revenue
  Total
Revenue
  Percentage of
Revenue
  Total
Revenue
  Percentage of
Revenue
Geographic Location:                                                
United States   $ 76,621       82 %   $ 92,259       87 %   $ 58,490       78 %
Europe     8,756       9 %     6,215       6 %     7,412       10 %
Other     7,622       9 %     7,121       7 %     9,179       12 %
Total   $ 92,999       100 %   $ 105,595       100 %   $ 75,081       100 %

 

 

 

 

The Company recorded licensing, milestone, and contract revenue of $5.3 million, $30.1 million and $3.3 million for the years ended December 31, 2015, 2014, and 2013, respectively. Substantially all licensing, milestone, and contract revenue was derived in the United States for each year presented.

 

 

 

Net long-lived assets, consisting of net property and equipment, are subject to geographic risks because they are generally difficult to move and to effectively utilize in another geographic area in a reasonable time period and because they are relatively illiquid. Net tangible long-lived assets by principal geographic areas were as follows (in thousands):

 

 

 

 

 

    Years Ended December 31,
    2015   2014
United States   $ 39,732     $ 31,059  
Italy     376       610  
Total   $ 40,108     $ 31,669  

 

EarningsPerSharePolicyTextBlock

5. Earnings per Share (“EPS”)

 

 

 

Basic EPS is calculated by dividing net income by the weighted average number of shares outstanding during the period. Unvested restricted shares, although legally issued and outstanding, are not considered outstanding for purposes of calculating basic earnings per share. Diluted EPS is calculated by dividing net income by the weighted average number of shares outstanding plus the dilutive effect, if any, of outstanding stock options, stock appreciation rights (“SAR’s”), restricted shares, and restricted stock units using the treasury stock method.

 

 

 

The following table provides share information used in the calculation of the Company's basic and diluted earnings per share (in thousands):

 

 

 

 

 

    Years Ended December 31,
    2015   2014   2013
Shares used in the calculation of basic earnings per share     14,934       14,678       14,087  
Effect of dilutive securities:                        
Stock options, SARs, and RSAs     387       591       739  
Diluted shares used in the calculation of earnings per share     15,321       15,269       14,826  

 

 

 

 

Stock options to purchase 197,691 shares, 129,540 shares, and 21,326 shares for 2015, 2014, and 2013, respectively, were excluded from the computation of diluted EPS as their effect would have been anti-dilutive.

 

 

 

At December 31, 2015, 2014, and 2013, 62,825 shares, 30,700 shares, and 52,339 shares of issued and outstanding unvested restricted stock, respectively, were excluded from the basic earnings per share.